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Abstract
Background: In the last years, plants are being used for the production of a wide variety of biopharmaceuticals, 
including cytokines, and have the potential to serve as vehicles for mucosal administration of these molecules. We had 
previously reported the expression of a cytokine, interleukin-12 (IL-12), in transgenic tomato plants and had 
demonstrated that it retained its biologic activity in vitro.
Findings: In this work, we administered crude extracts of IL-12-containing tomato fruits to mice through the 
intratracheal route, measuring endogenous IL-12 and determining biologic activity by quantification of interferon-
gamma (IFN-γ) in lungs and by histological analysis. IFN-γ expression in lungs, as well as histological analysis, indicate 
that tomato-expressed IL-12 retains its biologic activity and, most importantly, its effects are restricted to the site of 
administration.
Conclusion: Our results indicate that the functional activity of tomato-expressed IL-12 is comparable to that of 
commercial recombinant IL-12 when given via the mucosal route. This opens the possibility of using crude extracts 
prepared from tomatoes expressing IL-12 for certain immunotherapies.
Background
Interleukin-12 (IL-12), a member of the heterodimeric
cytokine family, is a pro-inflammatory cytokine that
favours the differentiation of T helper 1 cells, promoting
cellular immune responses. The therapeutic potential of
IL-12 has been extensively examined using a variety of
animal models in vivo. IL-12 augments immune
responses to a variety of infectious agents known to be
controlled via cellular immunity, elicits significant antitu-
mor effects and, there is promising data supporting the
use of IL-12 as a vaccine adjuvant [1].
The limited use of IL-12 as a therapeutic agent is
mainly due to the fact that subcutaneous administration,
which is the route most common employed, is associated
with highly elevated levels of serum interferon-γ (IFN-γ)
that lead to significant toxicity. For this reason, there is
interest in identifying alternative approaches for IL-12
delivery that are efficacious without causing adverse
e f f e c t s .  I n  t h i s  r e g a r d ,  i t  h a s  b e e n  d e m o n s t r a t e d  t h a t
mucosal delivery of IL-12 induces much less toxicity than
parenteral administration, while maintaining the efficacy
[2]. This finding opens the need for suitable vehicles for
IL-12 mucosal administration.
Transgenic plants are excellent candidates as vehicles
for mucosal administration of therapeutic proteins and
offer some advantages over other expression systems,
such as low-cost inputs, feasibility of scaling up, reduc-
tion of health risks deriving from contamination with
human pathogens, simplification of downstream process-
ing and the ability to perform complex posttranslational
modifications [3]. To date, there are several publications
reporting the expression of cytokines in plants, including
IL-12, that fully retain their activity in vitro [4-7]. How-
ever, with only one exception, where tobacco extracts
expressing IL-10 were administered orally to mice [8],
experiments to evaluate in vivo activity of plant-based
cytokines have not yet been conducted.
In a previous work, we reported the generation of
transgenic tomato plants that express single-chain mouse
IL-12 and showed that this plant recombinant protein
displayed biologic activity in vitro, as determined by IFN-
γ production by T lymphocytes after the addition of
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transgenic plant crude extracts [9]. In the present study,
we examined tomato-expressed IL-12 for its in vivo activ-
ity, by delivering fruit crude extracts intratracheally to
mice. IFN-γ expression in lungs, as well as histological
analysis, indicate that tomato-expressed IL-12 retains its
biologic activity and, most importantly, its effects are
restricted to the site of administration.
Results and Discussion
Here we describe the in vivo activity of a single-chain IL-
12 expressed in an edible crop, the tomato. At present,
the crop that has been used the most for production of
immunomodulatory molecules is tobacco. This repre-
sents, however, an important disadvantage if the recom-
binant protein is intended to be administered without
purification, because of the presence of alkaloids in
tobacco extracts. For this reason, the use of edible crops
as factories for biopharmaceuticals is highly desirable,
particularly for mucosal administration. One interesting
approach is that reported by Menassa et al. [8], where IL-
10 was expressed in low alkaloid tobacco plants grown in
controlled environment chambers and its oral adminis-
tration significantly reduced the severity of inflammatory
bowel disease in a mouse model.
Since we originally planned to administer recombinant
murine IL-12 expressed in tomato fruits (tIL-12) without
purification, and considering that when free IL-12 beta
chain is found in excess, it has the capacity to form
homodimers that function as specific IL-12 antagonists,
we decided to express a single-chain IL-12 molecule
encoded by only one gene, ensuring this way that there
would be equivalent amounts of both IL-12 chains [10].
Due to the high IL-12 levels obtained in our transgenic
tomato fruits, as compared to those obtained for other
cytokines [4-6], it was possible to administer an adequate
intratracheal dose of IL-12 to mice in a small volume.
The time course of IL-12 levels was analyzed in lung
homogenates and serum at 2, 4, 8, 16 and 24 h after IL-12
treatment (tIL-12 and commercial recombinant, rIL-12).
IL-12 protein level in lungs was higher in mice treated
with IL-12 than that seen in control mice at all evaluated
time points (Figure 1A), which indicates that IL-12 was
successfully delivered to the lungs. In addition, small dif-
ferences in IL-12 levels between recombinant and plant
IL-12 treatments were observed. These differences may
be caused by the presence of proteases in tomato crude
extracts that moderately degrade IL-12 before it is
absorbed through respiratory epithelium. A 5% of weight
loss was observed on both IL-12 treatments by 24 h (data
not shown). Hypoglycemia and decreased food intake
have been observed previously in mice treated with IL-12
[11], and perhaps this is the explanation for the weight
loss in our experiments. The amount of IL-12 in sera was
undetectable in all treatments.
Since IL-12 has a half-life of 5 to 10 h [12], the predic-
tion was that exogenous IL-12 would alter INF-γ produc-
tion early in the lung. As shown in Figure 1B, INF-γ levels
increased significantly at 4 and 8 h in mice treated with
IL-12; tIL-12 and rIL-12 induced INF-γ levels in a similar
way. By 24 h, INF-γ in the lungs of IL-12-treated mice
decreased to the level determined in control mice. INF-γ
levels were undetectable in mice serum. This demon-
strates, on one hand, that both IL-12s had biological
activity and, on the other hand, the response was locally
confined.
Our results clearly indicate that plant-expressed IL-12,
like recombinant IL-12, was successfully delivered to the
lungs, as observed by the IL-12 increase in mice treated
with tomato fruit crude extracts or recombinant IL-12.
Both IL-12s induced the production of comparable IFNγ
levels and the response was induced in a local fashion,
according to the absence of IL-12 and IFNγ levels in
peripheral blood of treated mice. This observation sup-
port that of Huber et al. [2], where intranasal IL-12
administration had no effects on serum IFNγ levels,
Figure 1 Changes in IL-12 and INF-γ levels over time in IL-12-
treated mice. BALB/c mice were administered with either tIL-12 or rIL-
12 as described in the methods section and sacrificed 2, 4, 8, 16 and 24 
h after treatment and their lungs removed. Whole lung homogenates 
were prepared and IL-12 (A) and INF-γ (B) assayed by ELISA. Mice treat-
ed with extracts from a non-transgenic wild type tomato (wt) were in-
cluded as controls. Results are given as mean ± SEM (n = 4 for each 
group). * P < 0.05 vs control.
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which correlates with IL-12 reduced toxicity. However, a
mild toxicity was observed in mice treated with plant-
expressed IL-12 as well as recombinant IL-12, according
to a slight weight loss in both treatments (data not
shown).
After 2 h of intratracheal administration of tIL-12 or
non-transgenic control extracts, mice lungs showed occa-
sional patches of eosinophilic fibrilar material into alveo-
lar spaces with few neutrophils (Figure 2A), while no
significant histological changes were seen in mice that
received rIL-12. Two hours later, perivenular inflamma-
tion and alveolar spaces with fibrilar material surrounded
by neutrophils and macrophages were seen in mice
treated with tIL-12 or wt extracts. At 12 h and, more evi-
dently, 24 h after the intratracheal administration of tIL-
12, mice lung showed nodular patches of intralveolar
inflammation constituted by activated macrophages
(large cells with compact cytoplasm and big nucleus with
marginated chromatin and apparent nucleoli) sur-
rounded by lymphocytes (Figure 2B). Similar inflamma-
tory infiltrates were seen in the lung of mice that received
rIL-12 (Figure 2C); bronchioli and blood vessels were sur-
rounded by inflammatory cells (Figure 2D).
It is important to mention that the results presented
here are from a single dose of 100 ng IL-12; nevertheless,
we first tested a dose-response relationship between IL-
12 administration and IFN-γ production, but no increase
in IFN-γ levels was observed when using IL-12 doses
higher than 100 ng (data not shown).
Figure 2 Representative histological features of lung sections stained with hematoxylin-eosin after intratracheal administration of rIL-12, 
tIL-12 and non-transgenic wild type tomato extract. Lung sections 2 h after administration of non-transgenic wild type tomato extracts (A), 12 h 
after tIL-12 administration (B), where alveoli with fibrilar material mixed with activated macrophages (arrows) and lymphocytes are seen, and 24 h after 
rIL-12 administration (C, D). Some venules (V) and bronchioles (B) are surrounded by inflammatory cells (arrows).
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In conclusion, we showed in this report that tomato-
expressed IL-12 displays a functional activity that is simi-
lar to that of recombinant IL-12 in vivo when adminis-
tered through a mucosal route. This opens the possibility
of using crude extracts prepared from tomatoes express-
ing IL-12 for certain immunotherapies where the induc-
tion of a Th1 response is necessary. To this respect, the
therapeutic effects of plant-based IL-12 were evaluated
by oral administration of tomato extracts to mice infected
with Mycobacterium tuberculosis and it was found that
plant-based IL-12 reduced lung mycobacterial loads, as a
consequence of an effective induction of a Th1 response
by IL-12 [13]. Finally, we are currently testing the efficacy
of plant-based IL-12 in the control of human respiratory
syncytial virus infection in a mouse model.
Methods
Animals
Male BALB/c mice at 6-8 weeks of age were maintained
in pathogen-free conditions according to guidelines of
the Ethical Committee for Experimentation in Animals of
the National Institute of Medical Sciences and Nutrition
in Mexico.
Plant extract preparation
Tomato fruit extracts from line IL12-1, generated by
Agrobacterium-mediated transformation with binary
plasmid p35SMIL12-2300, as reported elsewhere [9],
were prepared as follows: 2 volumes of ice-cold extraction
buffer (0.01 M Na2HPO4, 0.003 M KH2PO4, 0.1 M NaCl
and 0.025 M sodium ascorbate) were added to fruit tissue
previously ground in liquid nitrogen, crude extracts were
centrifuged at 10,000 rpm for 10 min at 4°C and cleared
supernatans were filtered through sieve cloth and lyo-
philized. Lyophilized extracts were reconstituted in 0.2
μM-filtered, deionized water and IL-12 levels were deter-
mined by ELISA with a commercial kit (BD Biosciences,
San Diego CA).
IL-12 treatment
Recombinant murine IL-12 expressed in tomato fruits
(tIL-12) or commercial recombinant IL-12 (Sigma, St.
Louis, MO) (rIL-12) were administered dissolved in PBS
by direct intratracheal cannulation in a single dose (100
ng). Control mice were treated with extracts from a non-
transgenic plant (wt), using the same amount of protein
as in tomato IL-12 extracts. Groups of 4 mice were anaes-
thetized with sevofluorane vapors (Abbott Laboratories,
México) and immobilized on cardboard. Then, tomato
extracts or recombinant cytokine were administered
using a rigid stainless steel cannula (Thomas Scientific,
Swedesboro, NJ) connected to an insulin syringe. The
cannula was introduced into the mouth and then directly
into the trachea. Mice were maintained in vertical posi-
tion until the effect of the anesthesia passed. Lung and
serum samples were harvested at various times after IL-
12 treatment (2, 4, 8, 16 and 24 h). Two independent
experiments were performed.
ELISAs
Whole lung homogenates were prepared using a tissue
homogenizer (Kinematica, Luzern, Switzerland) and 1 ml
of PBS. Levels of IL-12 and INF-γ were measured using
commercial available ELISA kits (BD Biosciences, San
Diego CA), following the manufacturer's instructions.
The limit of detection of the assay was 62.5 pg/ml of IL-
12 and 31.3 pg/ml of INF-γ.
Histological analysis
Mouse lungs were perfussed with 100% ethanol via the
trachea and removed for histological analysis. Paraffin-
embedded tissue was sectioned to a thickness of 5 μm
and stained with hematoxylin and eosin. Histopathology
of various tissues was evaluated in a blinded fashion.
Statistics
Numerical results were expressed as means ± SEM. Pairs
of groups were compared by Student's t-test and signifi-
cance was determined with P values < 0.05.
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